Forward Looking Statements and Industry Data

Unless the context otherwise requires, the terms “Trulieve,” “we,” “us” and “our” in this presentation refer to Trulieve Cannabis Corp. and its subsidiaries.

Certain statements in this presentation constitute forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and applicable Canadian securities legislation (collectively herein referred to as “forward-looking statements”), which can often be identified by words such as “will”, “may”, “estimate”, “expect”, “plan”, “project”, “intend”, “anticipate” and other words indicating that the statements are forward-looking. These forward looking statements relate to Trulieve’s expectations or forecasts of business, operations, financial performance, prospects, and other plans, intentions, expectations, estimates, and beliefs and include statements regarding Trulieve’s expected revenue and adjusted EBITDA for fiscal 2022, adjusted gross margin and adjusted EBITDA margin in its Long Term Model, its plans for expansion, potential acquisitions and expansion of the Company’s operations. Such forward-looking statements are expectations only and are subject to known and unknown risks, uncertainties and other important factors, including, but not limited to, risk factors included in this presentation, that could cause the Company’s actual results, performance or achievements or industry results to differ materially from any future results, performance or achievements implied by such forward-looking statements. Such risks and uncertainties include, among others, dependence on obtaining and maintaining regulatory approvals, including acquiring and renewing state, local or other licenses; engaging in activities which currently are illegal under United States federal law and the uncertainty of existing protection from United States federal or other prosecution; regulatory or political change such as changes in applicable laws and regulations, including United States state-law legalization, particularly in Florida, due to inconsistent public opinion, perception of the medical-use and adult-use cannabis industry, bureaucratic delays or inefficiencies or any other reasons; any other factors or developments which may hinder market growth; reliance on management; and the effect of capital market conditions and other factors on capital availability; competition, including from more established or better financed competitors; and the need to secure and maintain corporate alliances and partnerships, including with customers and suppliers. These factors should be considered carefully, and readers are cautioned not to place undue reliance on such forward-looking statements. You are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Although it may voluntarily do so from time to time, the Company undertakes no commitment to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable securities laws.

Unless otherwise noted, the forecasted industry and market data contained herein are based upon management estimates and industry and market publications and surveys. The information from industry and market publications has been obtained from sources believed to be reliable, but there can be no assurance as to the accuracy or completeness of the included information. The Company has not independently verified any of the data from third-party sources, nor has the Company ascertained the underlying economic assumptions relied upon therein. While such information is believed to be reliable for the purposes used herein, the Company makes no representation or warranty with respect to the accuracy of such information.

PLEASE NOTE: MARIJUANA IS ILLEGAL UNDER U.S. FEDERAL LAW, INCLUDING ITS CONSUMPTION, POSSESSION, CULTIVATION, DISTRIBUTION, MANUFACTURING, DISPENSING, AND POSSESSION WITH INTENT TO DISTRIBUTE.

Forward-looking statements made in this document are made only as of the date of their initial publication, and the Company undertakes no obligation to publicly update any of these forward-looking statements as actual events unfold.
Management’s Use of Non-GAAP Financial Measures

In addition to our results determined in accordance with GAAP, we supplement our results with non-GAAP financial measures, including adjusted gross profit, adjusted net income, adjusted net income per diluted share, and adjusted cash flow from operations. Our management uses these non-GAAP financial measures in conjunction with GAAP financial measures to evaluate our operating results and financial performance. We believe these measures are useful to investors as they are widely used measures of performance and can facilitate comparison to other companies. These non-GAAP financial measures have limitations as analytical tools in that they do not reflect all of the amounts associated with our results of operations as determined in accordance with GAAP. Because of these limitations, these non-GAAP financial measures should be considered along with GAAP financial performance measures. The presentation of these non-GAAP financial measures is not intended to be considered in isolation or as a substitute for, or superior to, financial information prepared and presented in accordance with GAAP. Investors are encouraged to review the reconciliation of these non-GAAP financial measures to their most directly comparable GAAP financial measures. A reconciliation of the non-GAAP financial measures to such GAAP measures can be found below. These non-GAAP financial measures should be considered supplemental to, and not a substitute for, our reported financial results prepared in accordance with GAAP.
167 Dispensaries (as of May 31, 2022)

11 States (including GA Notice of Intent to Award Class 1 Production License)

>4.0M ft² Cultivation and Processing (as of March 31, 2022)

17 Consecutive quarters profitability (through March 31, 2022)
Trulieve At A Glance

Trulieve is a leading vertically integrated U.S. multi-state cannabis operator
• Founded in 2014
• First Florida licensed operator with initial sales in 2016
• Completed RTO on CSE in September 2018

Established operations across three regional hubs: Southeast, Northeast, and Southwest
• >4.0 million square feet of cultivation and processing capacity as of March 31, 2022
• 167 open retail dispensaries as of May 31, 2022
• >9,000 Employees as of March 31, 2022

Excellent track record of profitable growth and prudent capital allocation
• 17 consecutive profitable quarters through March 2022
• Targeted approach with balance between organic growth and M&A
• Disciplined capital allocation with adherence to strategy and criteria
Vision, Mission, and Purpose

**Vision**
We aspire to be the leading customer-focused cannabis brand in the United States, with depth in the markets we choose to operate in.

**Mission**
We aim to provide the highest level of cannabis products and customer experience through authentic and reciprocal relationships.

**Purpose**
We exist to cultivate human potential.
Growth Initiatives
Strategic Priorities

Deliver Exceptional Customer Experiences and Build Brand Loyalty
• Provide superb service, expedient transactions, and frictionless returns
• Innovate across product and consumer categories

Expand through Hub Strategy
• Invest in cornerstone markets: Florida, Pennsylvania, and Arizona
• Expand in new and existing markets
• Pursue organic license awards and strategic M&A opportunities

Distribute Branded Products through Branded Retail and Wholesale Channels
• Expand distribution of branded products through branded retail locations
• Convert acquired, affiliated and/or operated retail locations to Trulieve brand
• Develop and expand wholesale channels with initial emphasis on AZ, MA, MD, PA

Focus on Profitable Growth and Create Shareholder Value
Customer Experience and Brand Loyalty

- **Customer Experience**
  - Service, convenience, frictionless returns
  - Customer loyalty rewards
  - High quality products, broad selection
- **New and innovative products**
  - Clones (MA only)
  - Refined Crème, TruTonic powdered drink mix, and TruWax
  - Live Budder, Live Diamonds, Live Meringue, Live Resin, Live Sauz carts, Live Suga
  - Mini pre-rolls
  - Ratio products, including CBG and CBN
  - Value sized edibles
  - Primo buds
Regional Hubs: Cultivation, Processing, Retail Capacity

167 Stores
As of May 31, 2022
All stores owned, operated, or affiliated
>4.0 M ft² Cultivation & Processing
As of March 31, 2022

Operational
Arizona
California
Colorado
Connecticut
Florida
Massachusetts
Maryland
Nevada
Pennsylvania
West Virginia
Pre-Revenue
Georgia

SOUTHWEST
22 stores
>0.4M ft²
cultivation & processing

NORTHEAST
29 stores
>0.5M ft²
cultivation & processing

SOUTHEAST
115 stores
>3.1M ft²
cultivation & processing
Cornerstone Markets: Florida, Pennsylvania, Arizona

- Limited license markets
- Leading market presence in retail
- Cultivation, processing and manufacturing operations
- Potential for expansion and optimization
- Potential future catalysts with adult use expansion in Florida and Pennsylvania
- Fast and favorable returns on capital investments
Cornerstone Market: Florida

**Limited License Medical Market**

- Trulieve operates 115 medical dispensaries
- Florida market has 22 vertical licenses issued and 436 approved dispensaries as of May 27, 2022
- Cultivation and processing capacity expansion is ongoing
- Increasing production of differentiated products across all segments and form factors in response to customer preferences
- Opening additional dispensaries and relocate up to six dispensaries in 2022
Cornerstone Market: Pennsylvania

Limited License Medical Market

• 19 affiliated retail locations

• Pennsylvania market has 50 retail permits (3 locations per permit), 25 grower/processor licenses, and up to 10 research/clinical permits

• Ongoing expansion of indoor cultivation and processing capacity through affiliated facilities

• Launched ground flower and minis in Q1 2022, Muse concentrates in April and additional launches pending approvals

• Wholesale distribution to 100% of the PA market
Cornerstone Market: Arizona

**Limited License Adult Use and Medical Market**
- Trulieve operates 17 retail dispensaries
- Arizona market has 131 core vertical licenses, 13 rural/underserved county licenses, and 26 future social equity licenses
- Expansion of cultivation and processing ongoing
- Plan to open two additional locations in 2022
Distribution of Branded Products through Branded Retail and Wholesale Channels

Trulieve Brands

VALUE                       MID                       PREMIUM

PREMIUM

AVENUE™

MID

MOMENTA

VALUE

Roll One

loveli
Distribution of Branded Products through Branded Retail and Wholesale Channels

Partner Brands
Leadership
Executive Leadership

KIM RIVERS
Founder, Chairman, Chief Executive Officer
Over 15 years of experience running successful businesses from real estate to finance. Legal background in M&A and securities law. Rivers serves as second vice chair for the National Cannabis Roundtable.

ALEX D’AMICO
Chief Financial Officer
Over 20 years of accounting and finance experience in technology, healthcare, entertainment and advertising. He has held several senior finance and executive roles at Cognizant, Deloitte, Quest Diagnostics, Synvista Therapeutics and Telaria.

TIM MOREY
Chief Sales Officer
Over 20 years of retail leadership and operations experience with prior roles at Foot Locker, Finish Line and Gamestop.

KYLE LANDRUM
Chief Production Officer
Joined Trulieve in 2017 and has 15 years of experience with multi-state operations management. He has successfully led large teams to achieve company goals, overseeing rapid growth and expansion.

STEVE WHITE
President
Over 10 years of cannabis experience as CEO and Co-Founder of Harvest Health & Recreation with legal background as former litigator. Pioneer in advancement of regulated cannabis industry.

ERIC POWERS
Chief Legal Officer
Over 25 years of broad legal experience with a background in corporate and tax law, both in-house and private practice including senior roles at Crawford & Company.

KIM RIVERS
Founder, Chairman, Chief Executive Officer
Over 15 years of experience running successful businesses from real estate to finance. Legal background in M&A and securities law. Rivers serves as second vice chair for the National Cannabis Roundtable.

ALEX D’AMICO
Chief Financial Officer
Over 20 years of accounting and finance experience in technology, healthcare, entertainment and advertising. He has held several senior finance and executive roles at Cognizant, Deloitte, Quest Diagnostics, Synvista Therapeutics and Telaria.

TIM MOREY
Chief Sales Officer
Over 20 years of retail leadership and operations experience with prior roles at Foot Locker, Finish Line and Gamestop.

KYLE LANDRUM
Chief Production Officer
Joined Trulieve in 2017 and has 15 years of experience with multi-state operations management. He has successfully led large teams to achieve company goals, overseeing rapid growth and expansion.

STEVE WHITE
President
Over 10 years of cannabis experience as CEO and Co-Founder of Harvest Health & Recreation with legal background as former litigator. Pioneer in advancement of regulated cannabis industry.

ERIC POWERS
Chief Legal Officer
Over 25 years of broad legal experience with a background in corporate and tax law, both in-house and private practice including senior roles at Crawford & Company.
Board of Directors

**KIM RIVERS**, Founder, Chairman, Chief Executive Officer
Experienced entrepreneur with successful track record in multiple sectors including cannabis and real estate. Rivers joined Trulieve at its inception and has been the key driver for the Company’s customer-centric vision, strong growth, strategic expansion, and industry-leading profitability. Prior to Trulieve, Ms. Rivers spent several years as an attorney in private practice specializing in mergers, acquisitions, and securities for multi-million-dollar corporations.

**GIANNELLA ALVAREZ**, Director
Experienced executive with focus on strategic planning, branding, innovation, consumer insights, technology, and scaling and leading multi-billion-dollar businesses. Previously CEO of Beanitos, Inc., a privately held snack food company, and Harmless Harvest, Inc., a privately held organic food and beverage company. Her experience includes senior global leadership roles at The Coca-Cola Company, The Procter and Gamble Co. and Kimberly Clark.

**RICHARD MAY**, Director
President and Co-Owner of May Nursery, Inc. with almost two decades of growing and management experience.
May has served on several agricultural and civic boards including the Southern Nursery Association and the Gadsden County Chamber of Commerce. May is a founding member of Trulieve.

**JANE MORREAU**, Director
Seasoned global finance executive with a broad skillset and expertise.
Experience includes supply chain management, manufacturing operations, information technology, retail operations, mergers and acquisitions and corporate strategy. Morreau formerly served as Executive Vice President and Chief Financial Officer of Brown-Forman Corporation.

**PETER T. HEALY**, Lead Director
Attorney with a focus on capital markets, M&A, and private equity transactions. Clients have included corporate issuers, Wall Street underwriters, and private equity firms.
Substantial experience representing issuers and underwriters in public offerings and private placements, private equity firms and sovereign wealth funds in their investment activities, and corporate boards in governance matters and strategic transactions.

**THAD BESHEARS**, Director
Co-Owner/President of Simpson Nurseries of FL and TN where he develops and implements strategic vision while monitoring the market for opportunities for growth and expansion.
Responsible for all sales operations, production, and inventory tracking. Under his guidance and oversight, the company has more than doubled annual sales.

**THOMAS MILLNER**, Director
Executive with strong combination of leadership, merchandising and multichannel experience.
Served as CEO of Cabela’s, a direct marketer and specialty retailer of outdoor recreation merchandise, for nearly a decade. Prior to Cabela’s, Milner spent 14 years as president and CEO of North Carolina’s Remington Arms Company.

**SUSAN THRONSON**, Director
Independent director with global digital, ecommerce and loyalty marketing experience.
Thronson was Senior Vice President of Global Marketing for Marriott International, leading Marriott’s worldwide integrated marketing strategy and execution for its 15 hotel brands.
Recent Developments

- Achieved record revenue, units sold, and number of customers served on 4/20 holiday
- Launched “4.20 For All” NFT collection
- Launched adult use sales at Napa, California dispensary
- Announced new brand partnership with DeLisioso Brands in Florida
- Expanded brand partnership with Khalifa Kush in Arizona
- Acquired West Virginia dispensary permit, expanding to 10 retail permits
- Trulieve opened 5 new dispensaries in Fort Myers and Zephyrhills, Florida, Framingham, Massachusetts, and Parkersburg and South Charleston, West Virginia
- Operate 167 retail dispensaries and >4.0 million square feet of cultivation and processing capacity as of May 31, 2022
Financial Highlights*

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Revenue</td>
<td>318.3</td>
<td>305.3</td>
<td>224.1</td>
<td>215.1</td>
<td>193.8</td>
<td>168.4</td>
<td>938.4</td>
<td>521.5</td>
</tr>
<tr>
<td>Gross Profit</td>
<td>178.2</td>
<td>132.4</td>
<td>153.9</td>
<td>144.5</td>
<td>135.3</td>
<td>119.9</td>
<td>566.1</td>
<td>386.4</td>
</tr>
<tr>
<td>Gross Margin</td>
<td>56.0%</td>
<td>43.4%</td>
<td>68.7%</td>
<td>67.2%</td>
<td>69.8%</td>
<td>71.2%</td>
<td>60.3%</td>
<td>74.1%</td>
</tr>
<tr>
<td>Adjusted Gross Profit</td>
<td>185.4</td>
<td>180.6</td>
<td>155.0</td>
<td>146.7</td>
<td>139.0</td>
<td>121.7</td>
<td>621.4</td>
<td>389.9</td>
</tr>
<tr>
<td>Adjusted Gross Margin</td>
<td>58.2%</td>
<td>59.1%</td>
<td>69.2%</td>
<td>68.2%</td>
<td>71.7%</td>
<td>72.2%</td>
<td>66.2%</td>
<td>74.8%</td>
</tr>
<tr>
<td>SG&amp;A</td>
<td>106.4</td>
<td>117.0</td>
<td>79.9</td>
<td>61.5</td>
<td>57.3</td>
<td>52.0</td>
<td>315.7</td>
<td>155.5</td>
</tr>
<tr>
<td>SG&amp;A as % Revenue</td>
<td>33.4%</td>
<td>38.3%</td>
<td>35.7%</td>
<td>28.6%</td>
<td>29.5%</td>
<td>30.9%</td>
<td>33.6%</td>
<td>29.8%</td>
</tr>
<tr>
<td>Adjusted SG&amp;A</td>
<td>95.1</td>
<td>96.4</td>
<td>67.6</td>
<td>57.6</td>
<td>52.6</td>
<td>45.0</td>
<td>274.3</td>
<td>144.2</td>
</tr>
<tr>
<td>Adjusted SG&amp;A as % Revenue</td>
<td>29.9%</td>
<td>31.6%</td>
<td>30.2%</td>
<td>26.8%</td>
<td>27.2%</td>
<td>26.7%</td>
<td>29.2%</td>
<td>27.6%</td>
</tr>
<tr>
<td>Depreciation and Amortization</td>
<td>29.3</td>
<td>28.3</td>
<td>7.7</td>
<td>6.7</td>
<td>5.4</td>
<td>4.0</td>
<td>48.1</td>
<td>12.6</td>
</tr>
<tr>
<td>Net Income (Loss)</td>
<td>(32.0)</td>
<td>(71.5)</td>
<td>18.6</td>
<td>40.9</td>
<td>30.1</td>
<td>3.0</td>
<td>18.0</td>
<td>63.0</td>
</tr>
<tr>
<td>Adjusted Net Income</td>
<td>1.7</td>
<td>1.8</td>
<td>36.2</td>
<td>47.0</td>
<td>38.5</td>
<td>41.8</td>
<td>123.4</td>
<td>120.5</td>
</tr>
<tr>
<td>EPS</td>
<td>(0.17)</td>
<td>(0.49)</td>
<td>0.14</td>
<td>0.31</td>
<td>0.24</td>
<td>0.03</td>
<td>0.12</td>
<td>0.53</td>
</tr>
<tr>
<td>Adjusted EPS</td>
<td>0.01</td>
<td>0.01</td>
<td>0.26</td>
<td>0.4</td>
<td>0.30</td>
<td>0.35</td>
<td>0.84</td>
<td>1.02</td>
</tr>
<tr>
<td>Adjusted EBITDA</td>
<td>105.5</td>
<td>100.9</td>
<td>98.0</td>
<td>94.9</td>
<td>90.8</td>
<td>81.4</td>
<td>384.6</td>
<td>260.1</td>
</tr>
<tr>
<td>Adjusted EBITDA Margin</td>
<td>33.2%</td>
<td>33.0%</td>
<td>43.7%</td>
<td>44.1%</td>
<td>46.8%</td>
<td>48.3%</td>
<td>41.0%</td>
<td>49.9%</td>
</tr>
</tbody>
</table>

*Adjusted Gross Profit, Adjusted Net Income, and Adjusted EBITDA are Non-GAAP financial measures. See slides 24-27 for reconciliation to GAAP for all Non-GAAP financial measures.
Financial Highlights

BALANCE SHEET HIGHLIGHTS
(USD millions) Q1:22 Q4:21 Q3:21 Q2:21 Q1:21 Q4:20
Cash 267 234 214 289 162 147
Debt 553 479 137 137 136 135

SHARE COUNT ESTIMATE
(millions as of March 31, 2022 on as if converted basis)
Subordinate Voting Shares 135.0
Multiple Voting Shares* 0.5
Total Shares Outstanding 184.2
*converted at 100 subordinate shares per 1 multiple voting share

Employee Stock Options/RSUs 4.5
Finance Warrants 2.6
Equity Warrants 1.0

excludes 2.059 million unexercisable options
excludes 1.132 million nonvested RSUs

Pro Forma Estimated Shares 192.3
Reconciliation of Non-GAAP Financial Measures

<table>
<thead>
<tr>
<th>(Amounts expressed in millions of United States dollars)</th>
<th>For the Three Months Ended</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>March 31, 2022</td>
</tr>
<tr>
<td>Net Income (Loss) GAAP</td>
<td>$ (32.0)</td>
</tr>
<tr>
<td>Add (Deduct) Impact of:</td>
<td></td>
</tr>
<tr>
<td>Interest Expense, net</td>
<td>$ 17.9</td>
</tr>
<tr>
<td>Provision For Income Taxes</td>
<td>$ 42.3</td>
</tr>
<tr>
<td>Depreciation and Amortization</td>
<td>$ 29.3</td>
</tr>
<tr>
<td>Depreciation in COGS</td>
<td>$ 10.7</td>
</tr>
<tr>
<td>EBITDA</td>
<td>$ 68.2</td>
</tr>
<tr>
<td>Inventory Step Up Fair Value</td>
<td>$ 0.4</td>
</tr>
<tr>
<td>Integration and Transition Costs</td>
<td>$ 5.3</td>
</tr>
<tr>
<td>Acquisition and Transaction Costs</td>
<td>$ 3.3</td>
</tr>
<tr>
<td>Share-Based Compensation</td>
<td>$ 4.6</td>
</tr>
<tr>
<td>Other Non-Recurring Expenses</td>
<td>$ 8.6</td>
</tr>
<tr>
<td>Covid Related Expenses</td>
<td>$ 0.4</td>
</tr>
<tr>
<td>Impairment and Disposal of Long-lived Assets</td>
<td>$ 2.7</td>
</tr>
<tr>
<td>Non-Controlling Interest</td>
<td>$ 0.0</td>
</tr>
<tr>
<td>Other Expense (Income), net</td>
<td>$ (0.9)</td>
</tr>
<tr>
<td>Fair Value of Derivative Liabilities - Warrants</td>
<td>$ (0.8)</td>
</tr>
<tr>
<td>Adjusted EBITDA Non-GAAP</td>
<td>$ 105.5</td>
</tr>
</tbody>
</table>
# Reconciliation of Non-GAAP Financial Measures

(Amounts expressed in millions of United States dollars)

<table>
<thead>
<tr>
<th></th>
<th>For the Three Months Ended</th>
<th>For the Full Year Ended</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>March 31, 2022</td>
<td>March 31, 2021</td>
</tr>
<tr>
<td><strong>Gross Profit GAAP</strong></td>
<td>$ 178.2</td>
<td>$ 135.3</td>
</tr>
<tr>
<td><strong>Gross Margin % GAAP</strong></td>
<td>56%</td>
<td>70%</td>
</tr>
<tr>
<td>Add (Deduct) Impact of:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inventory Step Up Fair Value</td>
<td>$ 0.4</td>
<td>$ 2.5</td>
</tr>
<tr>
<td>Transaction, Acquisition, and Integration Costs</td>
<td>$ 6.8</td>
<td>$ 1.2</td>
</tr>
<tr>
<td>Adjusted Gross Profit Non-GAAP</td>
<td>$ 185.4</td>
<td>$ 139.0</td>
</tr>
<tr>
<td>Adjusted Gross Margin % Non-GAAP</td>
<td>58%</td>
<td>72%</td>
</tr>
</tbody>
</table>
## Reconciliation of Non-GAAP Financial Measures

(Amounts expressed in millions of United States dollars)

<table>
<thead>
<tr>
<th></th>
<th>For the Three Months Ended</th>
<th>For the Full Year Ended</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>March 31, 2022</td>
<td>March 31, 2021</td>
</tr>
<tr>
<td>Net Income (Loss) GAAP</td>
<td>$ (32.0)</td>
<td>$ 30.1</td>
</tr>
<tr>
<td>Add (Deduct) Impact of:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Warrant Liability Adjustment</td>
<td>$ (0.8)</td>
<td>$ 0.0</td>
</tr>
<tr>
<td>Inventory Step Up Fair Value</td>
<td>$ 0.4</td>
<td>$ 2.5</td>
</tr>
<tr>
<td>Transaction, Acquisition, and</td>
<td>$ 17.2</td>
<td>$ 2.0</td>
</tr>
<tr>
<td>Integration Costs</td>
<td>$ 0.4</td>
<td>$ 3.8</td>
</tr>
<tr>
<td>Covid Related Expenses</td>
<td>$ 2.7</td>
<td>$ 0.0</td>
</tr>
<tr>
<td>Divestment and Sale of</td>
<td>$ 13.8</td>
<td>$ 0.0</td>
</tr>
<tr>
<td>Non-Operating Assets</td>
<td>$ 1.7</td>
<td>$ 38.4</td>
</tr>
<tr>
<td>Adjusted Net Income Non-GAAP</td>
<td>$ 1.8</td>
<td>$ 41.8</td>
</tr>
</tbody>
</table>

(Amounts expressed in millions of United States dollars)

|                                | For the Three Months Ended | For the Full Year Ended |
| Net Income (Loss) GAAP         | $ (71.5)       | $ 3.0         | $ 18.6            | $ 18.0             | $ 63.0             |
| Add (Deduct) Impact of:        |                |               |                  |                     |                     |
| Share-Based Compensation       | $ 0.0          | $ 0.0          | $ 4.2            | $ 4.2             | $ 0.0              |
| Warrant Liability Adjustment   | $ (0.2)        | $ 29.9        | $ 0.0            | $ (0.2)            | $ 42.7             |
| Inventory Step Up Fair Value   | $ 38.0         | $ 1.0         | $ 0.7            | $ 41.2             | $ 1.0              |
| Transaction, Acquisition, and  | $ 30.0         | $ 4.7         | $ 12.2           | $ 48.7             | $ 4.7              |
| Integration Costs              | $ 0.2          | $ 3.2         | $ 0.5            | $ 6.2              | $ 9.1              |
| Covid Related Expenses         | $ 5.4          | $ 0.0         | $ 0.0            | $ 5.4              | $ 0.0              |
| Impairment Intangible Assets   | $ 1.8          | $ 41.8        | $ 36.2           | $ 123.4            | $ 120.5            |

(Amounts expressed in millions of United States dollars)
## Reconciliation of Non-GAAP Financial Measures

(Amounts expressed in millions of United States dollars)

<table>
<thead>
<tr>
<th></th>
<th>For the Three Months Ended</th>
<th>For the Full Year Ended</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>March 31, 2022</td>
<td>March 31, 2021</td>
</tr>
<tr>
<td>Earnings (Loss) Per Share GAAP</td>
<td>$ (0.17)</td>
<td>$ 0.24</td>
</tr>
<tr>
<td>Add (Deduct) Impact of:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Warrant Liability Adjustment</td>
<td>$ 0.00</td>
<td>$ 0.00</td>
</tr>
<tr>
<td>Inventory Step Up Fair Value</td>
<td>$ 0.00</td>
<td>$ 0.02</td>
</tr>
<tr>
<td>Transaction, Acquisition, and Integration Costs</td>
<td>$ 0.09</td>
<td>$ 0.02</td>
</tr>
<tr>
<td>Covid Related Expenses</td>
<td>$ 0.00</td>
<td>$ 0.03</td>
</tr>
<tr>
<td>Divestment and Sale of Non-Operating Assets</td>
<td>$ 0.01</td>
<td>$ 0.00</td>
</tr>
<tr>
<td>Impairment and Disposal of Long-lived Assets</td>
<td>$ 0.07</td>
<td>$ 0.00</td>
</tr>
<tr>
<td>Adjusted Earnings Per Share Non-GAAP</td>
<td>$ 0.01</td>
<td>$ 0.30</td>
</tr>
</tbody>
</table>

(Amounts expressed in millions of United States dollars)

<table>
<thead>
<tr>
<th></th>
<th>For the Three Months Ended</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>December 31, 2021</td>
</tr>
<tr>
<td>Earnings (Loss) Per Share GAAP</td>
<td>$ (0.49)</td>
</tr>
<tr>
<td>Add (Deduct) Impact of:</td>
<td></td>
</tr>
<tr>
<td>Share-Based Compensation</td>
<td>$ 0.00</td>
</tr>
<tr>
<td>Warrant Liability Adjustment</td>
<td>$ 0.00</td>
</tr>
<tr>
<td>Inventory Step Up Fair Value</td>
<td>$ 0.26</td>
</tr>
<tr>
<td>Transaction, Acquisition, and Integration Costs</td>
<td>$ 0.21</td>
</tr>
<tr>
<td>Covid Related Expenses</td>
<td>$ 0.00</td>
</tr>
<tr>
<td>Impairment Intangible Assets</td>
<td>$ 0.04</td>
</tr>
<tr>
<td>Adjusted Earnings Per Share Non-GAAP</td>
<td>$ 0.01</td>
</tr>
</tbody>
</table>
Thank You